Skip to main content
. 2015 Jul 10;309(6):L593–L604. doi: 10.1152/ajplung.00029.2015

Fig. 3.

Fig. 3.

Systemic LPS disrupts pulmonary angiogenesis and decreases the expression of angiogenic factors, and inhibiting the NF-κB pathway accentuates these effects. A: representative immunofluorescent images from lung frozen sections obtained from PBS, LPS, and LPS + BAY-treated mice at 24 h, to detect CD31 (green) and chromatin (blue) (A) or von Willebrand factor (vWF; red) and chromatin (blue) (B). C: quantification of vWF-stained vessels per high power field (HPF) in each group with ***P < 0.001 vs. PBS. Data are expressed as means ± SE, with n = 5 to 6 for each group. D: Western immunoblot to detect VEGFR-2 and VEGF-A (E) in lung tissue from PBS, LPS, and LPS + BAY-treated mice at 24 h, and normalized to tubulin as a loading control, with **P < 0.01 and ***P < 0.001 vs. PBS. Dividing lines between bands on the VEGFR2 WB indicate that the bands were from the same gel, but not from adjacent wells. Data are expressed as means ± SE, with n = 4 for each group. Scale bar = 100 μm.